Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 14
Submit an article Journal homepage
218
Views
29
CrossRef citations to date
0
Altmetric
Review

Expert opinion on available options treating pulmonary arterial hypertension

Robert Naeije Professor and Chairman, Erasme University Hospital, Department of Pathophysiology, Erasme Campus, CP 604, 808, Lennik Road, B-1070 Brussels , Belgium +322 5553322; +322 5554124; [email protected]; Consultant, Erasme University Hospital, Department of Cardiology
&
Sandrine Huez Assistant, Erasme University Hospital, Department of Cardiology
, MD
Pages 2247-2265 | Published online: 10 Oct 2007

Bibliography

  • FARBER HW, LOSCALZO J: Pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351:1655-1665.
  • HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351:1425-1436.
  • MCLAUGHLIN V, PRESBERG KW, DOYLE RL et al.: Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126:S78-S92.
  • PROVENCHER S, SITBON O, HUMBERT M, CABROL S, JAIS X, SIMONNEAU G: Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. (2006) 27:589-595.
  • SIMONNEAU G, GALIE N, RUBIN LJ et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):S5-S12.
  • HUMBERT M, SITBON O, CHAOUAT A et al.: Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. (2006) 173:1023-1030.
  • ABENHAIM L, MORIDE Y, BRENOT F et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N. Engl. J. Med. (1996) 335:609-616.
  • BARST RJ, MCGOON M, TORBICKI A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl.):S40-S47.
  • NAEIJE R, VACHIERY JL: Medical therapy of pulmonary hypertension: conventional therapies. Clin. Chest Med. (2001) 22:517-528.
  • MERELES D, EHLKEN N, KREUSCHER S et al.: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation (2006) 114:1482-1489.
  • HOEPER MM, LEE SH, VOSWINCKEL R et al.: Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J. Am. Coll. Cardiol. (2006) 48:2546-2552.
  • BONNIN M, MERCIER FJ, SITBON O et al.: Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology (2005) 102:1133-1137.
  • OAKLEY C, SOMMERVILLE J: Oral contraceptives and pulmonary vascular disease. Lancet (1968) I:890-891.
  • NAEIJE R: Preflight medical screening of patients. Eur. Respir. J. (2000) 16:197-199.
  • SANDOVAL J, AGUIRRE JS, PULIDO T et al.: Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am. J. Respir. Crit. Care Med. (2001) 164:1682-1687.
  • KUEHNE T, YILMAZ S, STEENDIJK P et al.: Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation (2004) 110:2010-2016.
  • PROVENCHER S, HERVÉ P, JAIS X et al.: Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology (2006) 130:120-126.
  • KERBAUL F, RONDELET B, MOTTE S et al.: Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit. Care Med. (2004) 32:1035-1040.
  • RICH S, KAUFMANN E, LEVY PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. (1992) 327:76-81.
  • RICH S, SEIDLITZ M, DODIN E et al.: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest (1998) 114:787-792.
  • WAGENVOORT CA, WAGENVOORT N: Primary pulmonary hypertension: a pathologic study of the lung vessels. Circulation (1970) 42:1163-1184.
  • FUSTER V, STEELE PM, EDWARDS WD et al.: Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation (1984) 70:580-587.
  • HYERS TM: Venous thromboembolism. Am. J. Respir. Crit. Care Med. (1999) 159:1-14.
  • RAFFY O, AZARIAN R, BRENOT F et al.: Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation (1996) 93:484-488.
  • SITBON O, HUMBERT M, JAIS X et al.: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 111:3105-3111.
  • MATHE AA, HEDQUIST P, STRANDBERG K, LESLIE CA: Aspects of prostaglandin function in the lung. N. Engl. J. Med. (1977) 296:850-855, 910-914.
  • LOCK JE, OLLEY PM, COCCEANI F, SWYER PR, ROWE RD: Use of prostacyclin in persistent fetal circulation. Lancet (1979) I:1343.
  • WATKINS WD, PETERSON MB, CRONE RK, SHANNON DC, LEVINE L: Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet (1980) I:1083.
  • RUBIN LJ, GROVES BM, REEVES JT, FROSOLONO M, HANDEL F, CATO AE: Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 66:334-338.
  • BLUMBERG FC, LORENZ C, WOLF K, SANDNER P, RIEGGER GA, PFEIFER M: Increased pulmonary prostacyclin synthesis in rats with chronic pulmonary hypertension. Cardiovasc. Res. (2002) 55:171-177.
  • ABE Y, TATSUMI K, SUGITO K, IKEDA Y, KIMURA H, KURIYAMA T: Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension. J. Cardiovasc. Pharmacol. (2001) 37:239-251.
  • SCHERMULY RT, YILMAZ H, GHOFRANI HA et al.: Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172:358-363.
  • TUDER RM, COOL CD, GERACI NW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159:1925-1932.
  • CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. (1992) 327:70-75.
  • HIGENBOTTAM TW, WHEELDON D, WELLS FC, WALLWORK J: Long-term treatment pf primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet (1984) I:1046-1047.
  • JONES KD, HIGENBOTTAM TW, WALLWORK J: Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br. Heart J. (1987) 57:270-278.
  • HIGENBOTTAM TW, SPIEGELHALTER D, SCOTT JP et al.: Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for sevee pulmonary hypertension. Br. Heart J. (1993) 70:366-370.
  • RUBIN LJ, MENDOZA J, HOOD M et al.: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann. Intern. Med. (1990) 112:485-491.
  • BARST RJ, RUBIN LJ, MCGOON MD, CALDWELL EJ, LONG WA, LEVY PS: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin Ann. Intern. Med. (1994) 121:409-415.
  • BARST, RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. (1996) 334:296-301.
  • SHAPIRO SM, OUDIZ RJ, CAO T et al.: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J. Am. Coll. Cardiol. (1997) 30:343-349.
  • BADESCH DR, TAPSON VF, MCGOON M et al.: Continuous intravenous epoprostenol for pulonary hypertension due to the scleroderma spectrum of disease. Ann. Intern. Med. (2000) 132:425-434.
  • ROSENZWEIG EB, KERSTEIN D, BARST RJ: Long-term prostacyclin for pulmonary hypertension and associated congenital heart defects. Circulation (1999) 14:1858-1865.
  • KUO PC, PLOTKIN JS, HOWELL CD, BARTLETT ST, RUBIN LJ: Continuous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation (1997) 63:604-606.
  • NUNES H, HUMBERT M, SITBON O et al.: Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2003) 167:1433-1439.
  • ROBBINS IM, CHRISTMAN BW, NEWMAN JH, MATLOCK R, LOYD JE: A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest (1998) 114:1269-1275.
  • Sitbon O, Humbert M, Nunes H et al.: Long-term intravenous epoprostenol in primary pulmonary hypertension. Prognostic factors and survival. J. Am. Coll. Cardiol. (2002) 40:780-788.
  • MCLAUGHLIN VV, SHILLINGTON A, RICH S: Survival in primary pulmonary hypertension. Circulation (2002) 106:1477-1482.
  • RICH S, MCLAUGHLIN V: The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J. Am. Coll. Cardiol. (1999) 34:1184-1187.
  • PALMER SM, ROBINSON LJ, WANG A, GOSSAGE JR, BASHORE T, TAPSON VE: Massive pulmonary edema and death after prostacyclin infusion in a patient with veno-occlusive disease. Chest (1998) 113:237-240.
  • HUMBERT M, MAITRE S, CAPRON F, RAIN B, MUSSET D, SIMONNEAU G: Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am. J. Respir. Crit. Care Med. (1998) 157:1681-1685.
  • VACHIERY JL, NAEIJE R: Treprostinil for pulmonary hypertension. Expert Rev. Cardiovasc. Ther. (2004) 2:183-189.
  • SIMONNEAU G, BARST RJ, GALIÉ N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2002) 162:800-804.
  • BARST RJ, GALIE N, NAEIJE R et al.: Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur. Respir. J. (2006) 28:1195-1203.
  • LANG I, GOMEZ-SANCHEZ M, KNEUSSL M et al.: Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest (2006) 129:1-8.
  • VACHIERY JL, HILL N, ZWICKE D, BARST R, BLACKBURN S, NAEIJE R: Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest (2002) 121:1561-12565.
  • GOMBERG-MAITLAND M, TAPSON VF, BENZA RL et al.: Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172:1586-1589.
  • CHANNICK RN, OLSCHEWSKI H, SEEGER W, STAUB T, VOSWINCKLE R, Rubin LJ: Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2006) 48:433-1437.
  • OLSCHEWSKI H, SIMONNEAU G, GALIÉ N et al.: Inhaled iloprost is an effective treatment for severe pulmonary hypertension. A double-blind, placebo-controlled, multicenter study. N. Engl. J. Med. (2002) 347:322-329.
  • HOEPER MM, SCHWARZE M, EHLERDING S et al.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. (2000) 342:1866-1870.
  • OPITZ CF, WENSEL R, WINKLER J et al.: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. (2005) 26:1895-1902.
  • HOEPER MM, SPIEKERKOETTER E, WESTERKAMP V, GATZKE R, FABEL H: Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur. Respir. J. (2002) 20:339-343.
  • GALIÉ N, HUMBERT M, VACHIÉRY JL et al.: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2002) 39:1496-1502.
  • BARST RJ, MCGOON M, MCLAUGHLIN V et al.: Beraprost study group. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41:2119-2125.
  • BERMAN ROSENZWEIG E, SCHMITT KA, GAROFANO R, BARST RJ: Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol. Chest (2004) 125:1157-1160.
  • MOTTE S, NAEIJE R, MCENTEE K: Endothelin receptor antagonists. Pharmacol. Ther. (2006) 110:386-414.
  • GIAID A, YANISAGAWA M, LANGLEBEN D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1993) 328:1732-1739.
  • RONDELET B, KERBAUL F, MOTTE S et al.: Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation (2003) 107:1329-1335.
  • BLACK SM, MATA-GREENWOOD E, DETTMAN RW et al.: Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation (2003) 108:1646-1654.
  • NISHIDA M, ESHIRO K, OKADA Y, TAKAOKA M, MATSUMURA Y: Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension. J. Cardiovasc. Pharmacol. (2004) 44:187-191.
  • IVY DD, YANAGISAWA M, GARIEPY CE, GEBB SA, COLVIN KL, MCMURTRY IF: Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am. J. Physiol. Lung Cell Mol. Physiol. (2002) 282:L703-L712.
  • CHEN SJ, CHEN IF, MENG QC, DURAND J, DI CARLO VS, OPARIL S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol. (1995) 79:2122-2131.
  • DICARLO VS, CHEN SJ, MENG QC et al.: ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am. J. Physiol. (1995) 269:L690-L697.
  • JASMIN JF, LUCAS M, CERNACEK P, DUPUIS J: Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation (2001) 103:314-318.
  • RONDELET B, KERBAUL F, VAN BENEDEN R et al.: Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension in piglets. Ped. Res. (2007) 61:284-288.
  • CLOZEL M, BREU V, GRAY GA et al.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1994) 270:228-235.
  • WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist bosentan in healthy subjects. Clin. Pharmacol. Ther. (1996) 60:124-137.
  • CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet (2001) 358:1119-1123.
  • RUBIN LJ, BADESCH RM, BARST R et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346:896-903.
  • GALIE N, HINDERLITER AL, TORBICKI A et al.: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41:1380-1386.
  • SITBON O, BADESCH DB, CHANNICK RN et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 124:247-254.
  • MCLAUGHLIN VV, SITBON O, BADESCH DB et al.: Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. (2005) 25:244-249.
  • SITBON O, MCLAUGHLIN VV, BADESCH DB et al.: Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax (2005) 60:1025-1230.
  • PROVENCHER S, SITBON O, HUMBERT M, CABROL S, JAIS X, SIMONNEAU G: Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur. Heart J. (2006) 27:589-595.
  • SITBON O, GRESSIN V, SPEICH R et al.: Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 170:1212-1217.
  • HOEPER MM, HALANK M, MARX C et al.: Bosentan therapy for portopulmonary hypertension. Eur. Respir. J. (2005) 25:502-508.
  • GALIE N, BEGHETTI M, GATZOULIS MA et al.: Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation (2006) 114:48-54.
  • ROSENZWEIG EB, IVY DD, WIDLITZ A et al.: Effects of long-term bosentan in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46:697-704.
  • FATTINGER K, FUNK C, PANTZE M et al.: The endothelin receptor antagonist bosentan inhibits the canalicular bile salt export pulmp: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. (2001) 69:223-231.
  • HUMBERT M, SEGAL ES, KIELY DG, CARLSEN J, SCHWIERIN B, HOEPER MM: Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. (2007) 30:338-344.
  • MODESTI PA, VANNI S, MORABITO M et al.: Role of endothelin-1 in exposure to high altitude: acute mountain sickness and endothelin-1 (ACME-1) study. Circulation (2006) 114:1410-1416.
  • HUMBERT M, BARST RJ, ROBBINS IM et al.: Combination of bosentan with epoprostenol in pulmonary arterial hypertension. Eur. Respir. J. (2004) 24:353-359.
  • HOEPER MM, MARKEVYCH I, SPIEKERKOETTER E, WELTE T, NIEDERMEYER J: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. (2005) 26:858-863.
  • MATHAI SC, GIRGIS RE, FISHER MR et al.: Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J. (2007) 29:469-475.
  • BARST RJ: Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother. (2007) 8:95-109.
  • BARST RJ, LANGLEBEN D, FROST A et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2005) 169:441-447.
  • BARST RJ, LANGLEBEN D, BADESCH D et al.: Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. (2006) 47:2049-2056.
  • PULIDO T, KURZINA M, SOUZA R, RAMIREZ A, SANDOVAL J: Sitaxsentan 100 mg proves more effective than sitaxsentan 50 mg in patients with pulmonary arterial hypertension. Proc. Am. Thorac. Soc. (2006) 3:A417.
  • BENZA RL, FROST A, GIRGIS D, LENGLEBEN D, LAWRENCE EC, NAEIJE R: Chronic treatment of pulmonary arterial hypertension (PAH) with sitaxsentan and bosentan. Proc. Am. Thorac. Soc. (2006) 3:A729.
  • BENZA RL, MEHTA S, KEOGH A et al.: Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J. Heart Lung Transplant. (2007) 26:63-69.
  • BILLMAN GE: Ambrisentan (Myogen). Curr. Opin. Investig. Drugs (2002) 3:1483-1486.
  • GALIE N, BADESCH D, OUDIZ R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46:529-535.
  • OUDIZ RJ, TORRES F, FROST AE et al.: ARIES-1: a placebo-controlled efficacy and safety study of administration of ambrisentan in patients with pulmonary arterial hypertension. Chest (2006) 130S:S121.
  • OLSCHEWSKI H, GALIÉ N, GHOFRANI HA et al.: Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study. Proc. Am. Thorac. Soc. (2006) 3:A728.
  • SEBKHI A, STRANGE JW, PHILIPS SC, WHARTON J, WILKINS M: Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 107:3230-3235.
  • SCHERMULY RT, KREISSELMEIER KP, GHOFRANI HA et al.: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. (2004) 169:39-45.
  • RONDELET B, KERBAUL F, VAN BENEDEN R et al.: Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation (2004) 110:2220-2225.
  • GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1995) 333:214-221.
  • WHARTON J, STRANGE JW, MOLLER GMO et al.: Anti-proliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. (2005) 172:105-113.
  • CARSON CC III: Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr. Urol. Rep. (1996) 4:488.
  • GHOFRANI HA, REICHENBERGER F, KOHSTALL MG et al.: Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest Base Camp. Ann. Intern. Med. (2004) 141:169-177.
  • ALDASHEV AA, KOJONAZAROV BK, AMATOV TA et al.: Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax (2005) 60:683-687.
  • GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 360:895-900.
  • GUAZZI M, TUMMINELLO G, DI MARCO F, FIORENTINI C, GUAZZI MD: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J. Am. Coll. Cardiol. (2004) 44:2339-2348.
  • ANTONIU SA: Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opin. Pharmacother. (2006) 7:1801-1810.
  • PAUL GA, GIBBS JS, BOOBIS AR, ABBAS A, WILKINS MR: Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. (2005) 60:107-112.
  • SASTRY BK, NARASIMHAN C, REDDY NK, RAJU BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. (2004) 43:1149-1153.
  • GALIE N, GHOFRANI H A, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353:2148-2157.
  • WILKINS MR, PAUL GA, STRANGE JW et al.: Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. (2005) 171:1292-1297.
  • REICHENBERGER F, VOSWINCKEL R, STEVELING E et al.: Sildenafil treatment for portopulmonary hypertension. Eur. Respir. J. (2006) 28:563-567.
  • GOMBERG-MAITLAND M, MCLAUGHLIN V, GULATI M, RICH S: Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am. J. Cardiol. (2005) 96:1334-1336.
  • HOEPER MM, FAULENBACH C, COLPON H, WINKLER J, WEITE T, NIEDERMEYER J: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. (2004) 24:1007-1010.
  • LACASSIE HJ, GERMAIN AM, VALDES G, FERNANDEZ MS, ALLAMAND F, LOPEZ H: Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet. Gynecol. (2004) 103:1118-1120.
  • HUMPL T, REYES JT, HOLTBY H, STEPHENS D, ADATHIA I: Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve month clinical trial of single-drug, open-label, pilot study. Circulation (2005) 111:3274-3280.
  • GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44:1488-1496.
  • ITOH T, NAGAYA N, FUJII T et al.: A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. (2004) 169:34-38.
  • CLOZEL M, HESS P, REY M, IGLARZ M, BINKERT C, QIU C: Bosentan, sildenafil and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp. Biol. Med. (2006) 231:967-973.
  • SCHERMULY RT, KREISSELMEIER KP, GHOFRANI HA et al.: Antiremodelling effects of iloprost and the dual selective phosphodiesterase III/IV inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. (2004) 94:1101-1108.
  • HUMBERT M, SIMONNEAU G: Sildenafil for pulmonary arterial hypertension: still awaiting the evidence. Am. J. Respir. Crit. Care Med. (2004) 169:6-7.
  • MCLAUGHLIN VV, OUDIZ RJ, FROST A et al.: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2006) 174:1257-1263.
  • HOEPER MM, LEUCHTE H, HALANK M et al.: Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Resp. J. (2006) 28:691-694.
  • SIMONNEAU G, BURGESS G, COLLINGS L et al.: Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). Proc. Am. Thorac Soc. (2006) 3:A58.
  • TANTINI B, MANES A, FIUMANA E et al.: Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res. Cardiol. (2005) 100:131-138.
  • ALI O, WHARTON J, GIBBS JS, HOWARD L, WILKINS MR: Emerging therapies for pulmonary arterial hypertension. Expert Opin. Investig. Drugs (2007) 16:803-818.
  • SCHERMULY RT, DONY E, GHOFRANI HA et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. (2005) 115:2811-2821.
  • GHOFRANI HA, SEEGER W, GRIMMINGER F: Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353:1412-1413.
  • PETKOV V, MOSGOELLER W, ZIESCHE R et al.: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. (2003) 111:1339-1346.
  • ZHAO YD, COURTMAN DW, DENG Y, KUGATHASAN L, ZHANG O, STEWART DJ: Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ. Res. (2005) 96:442-450.
  • DOGGRELL SA: Rho-kinase inhibitors show promise in pulmonary hypertension. Expert Opin. Investig. Drugs (2005) 14:1157-1159.
  • HERVÉ P, LAUNAY JM, SCROBOHACI ML et al.: Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. (1995) 99:249-254.
  • ABENHAIM L, MORIDE Y, BRENOT F et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. (1996) 335:609-616.
  • MARCOS E, ADNOT S, PHAM MH et al.: Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2003) 168:487-493.
  • KAO PN: Simvastatin treatment of pulmonary hypertension. An observational case series. Chest (2005) 127:1446-1452.
  • SANDOVAL J, ROTHMAN A, PULIDO T: Atrial septostomy for pulmonary hypertension. Clin. Chest Med. (2001) 22:547-560.
  • RASHKIND WJ: Atrial septostomy in congenital heart disease. Adv. Pediatr. (1969) 16:211-232.
  • RICH S, DODIN E, MCLAUGHLIN VV: Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am. J. Cardiol. (1997) 80:369-371.
  • CORRIS PA: Lung transplantation. In: Pulmonary Circulation. Diseases and their Treatment. 2nd Edition. Peacock AJ, Rubin LJ (Eds), Arnold, London (2004):309-318.
  • GALIE N, SEEGER W, NAEIJE R, SIMONNEAU G, RUBIN LJ: Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):S81-S88.
  • BADESCH DB, ABMAN SH, SIMONNEAU G, RUBIN LJ, MCLAUGHLIN V: Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest (2007) 131:1917-1928.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.